Update on Kaposi's sarcoma: A gammaherpesvirus-induced malignancy

Pallavi P. Kumar, Richard F. Little, Robert Yarchoan

Research output: Contribution to journalReview articlepeer-review

Abstract

Since the beginning of the AIDS epidemic, Kaposi's sarcoma (KS) has been one of the most visible manifestations of this disease and one of the most distressing for affected patients. The discovery in 1994 of a new gamma-herpesvirus, called Kaposi's sarcoma-associated herpes-virus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy. In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in countries where it is available and on the course of established disease. Finally, recent advances in our understanding of angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches that are now under development.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
JournalCurrent Infectious Disease Reports
Volume5
Issue number1
DOIs
StatePublished - Feb 2003

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Update on Kaposi's sarcoma: A gammaherpesvirus-induced malignancy'. Together they form a unique fingerprint.

Cite this